# Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease

> **NCT01593527** · PHASE3 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Acute Gouty Arthritis

## Interventions

- **DRUG:** ACZ885
- **DRUG:** Triamcinelone acetonide

## Key facts

- **NCT ID:** NCT01593527
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-09
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01593527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01593527, "Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01593527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*